Insulet Corporation

PODD · Nasdaq · ·

Karşılaştır

$149,25-%0,512 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 4 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: +%1,9
1M: +%11,4

Just reported

Q3 2026 results

From Insulet's results release of 4 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$842M
+%19 y/y
+%5,0 q/q
Guided
—
No guide given
EPS, GAAP
Actual
$2,03
+%64 y/y
+%48 q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$189,8M
+%61 y/y
+%46 q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Insulet is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Seçki
Medical devices
InspectStocks tarafından · 20 companies
Surgical robots, implants, heart devices, glucose monitors and other medical equipment.
Fiyat, 1 yıl
+%2,7
Gelir, 1 yıl
+%7,2
+14
A 8B 7C 3D 2

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

All 133 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Tüm finansal tablolar →

Insulet Corporation şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Insulet Corporation

Insulet Corporation

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP